Valuation : Alector, Inc.

Market Cap 261M 225M 211M 193M 363M 24.97B 364M 2.5B 977M 12.61B 981M 960M 41.8B P/E 2026 *
-2.73x
P/E 2027 * -3.36x
Enterprise Value 33.81M 29.13M 27.32M 24.93M 46.97M 3.23B 47.12M 324M 126M 1.63B 127M 124M 5.41B EV / Sales 2026 *
3.08x
EV / Sales 2027 * -1.36x
Free-Float
90.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Alector, Inc.

1 day-2.09%
1 week-0.85%
Current month+54.97%
1 month+53.95%
3 months+8.33%
6 months-3.70%
Current year+50.00%
1 week 2.26
Extreme 2.26
2.52
1 month 1.46
Extreme 1.455
2.52
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 71 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap.
8/19/26 Don

Founder

-2,100,000 1.8915%
7/9/26 Free

Controller/Auditor

20,000 0.0180%
6/3/26 Sell

Controller/Auditor

-3,475 0.0031%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-0.85%-0.43%-58.66% 261M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -2.03%-1.82%+51.95%+166.50% 28.22B
Weighted average by Cap. -1.93%-1.50%+53.68%+151.32%

Financials

2026 *2027 *
Net sales 10.98M 9.46M 8.87M 8.1M 15.25M 1.05B 15.3M 105M 41.05M 530M 41.21M 40.31M 1.76B 26.17M 22.55M 21.14M 19.3M 36.36M 2.5B 36.47M 251M 97.86M 1.26B 98.25M 96.11M 4.19B
Net income -96.86M -83.46M -78.25M -71.43M -135M -9.26B -135M -928M -362M -4.67B -364M -356M -15.49B -98.04M -84.48M -79.21M -72.3M -136M -9.37B -137M -940M -367M -4.73B -368M -360M -15.68B
Net Debt -227M -196M -184M -168M -316M -21.74B -317M -2.18B -851M -10.97B -854M -835M -36.39B -297M -256M -240M -219M -412M -28.36B -414M -2.84B -1.11B -14.32B -1.11B -1.09B -47.47B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-08-28 $2.340 -2.09% 542,221
26-08-27 $2.390 -2.85% 706,964
26-08-26 $2.460 +4.24% 996,494
26-08-25 $2.360 +2.61% 558,276
26-08-24 $2.300 -2.54% 738,144
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.340USD
Average target price
3.100USD
Spread / Average Target
+32.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock